ArticleTranslational cancer research2025
A novel disulfidptosis-related lncRNAs index to predict prognosis and therapeutic target in hepatocellular carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disulfidptosis: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Disulfidptosis in hepatocellular carcinoma: molecular mechanisms, therapeutic potential, and exploratory insights into chronic liver diseases.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Characterized by its significant occurrence and high fatality, hepatocellular carcinoma (HCC) presents a challenge with treatments frequently leading to less than ideal results. The mechanism of action behind disulfidptosis, a newly identified pathway of cell death, is not well comprehended when related to HCC. This research aims to investigate a model that employs long non-coding RNA (lncRNA) associated with disulfidptosis for predicting the prognosis of liver cancer and identifying potential therapeutic measures. Methods: The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) provided tissue specimens from 374 and 243 cases of HCC, respectively, along with samples from 50 and 202 healthy liver tissues. By employing differential analysis and Pearson correlation, we identified lncRNAs associated with disulfidptosis. Cox and least absolute shrinkage and selection operator (LASSO) regression analyses were then utilized to assess risk and construct a prognostic model for these lncRNAs. The model's predictive performance underwent evaluation through survival analysis, receiver operating characteristic (ROC), and C-index. Furthermore, our study delved into potential therapeutic roles of disulfidptosis-related lncRNAs in HCC, scrutinizing pathways, exploring the tumor microenvironment, and investigating immune evasion mechanisms. Results: The prognostic model that we developed comprises five lncRNAs associated with disulfidptosis: Conclusions: A prognostic model concerning disulfidptosis-related lncRNAs was constructed to predict outcomes in HCC. This model provides insights into molecular mechanisms, characterizes the tumor microenvironment, and predicts patient responses to immunotherapy and targeted treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.